Tower Research Capital (TRC)’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Tower Research Capital (TRC)’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,301	Closed	-$3K	–	5607
2015 Q4	$3K	Sell	2,301 -2,439	-51%	-$3.92K	﹤0.01%	3632
2015 Q3	$7K	Buy	4,740 +4,622	+3,917%	+$7.36K	﹤0.01%	2619
2015 Q2	$0	Sell	118 -284	-71%	-$474	﹤0.01%	5512
2015 Q1	$1K	Buy	+402	New	+$942	﹤0.01%	4276
2014 Q4	–	Sell	-2,007	Closed	-$2K	–	5252
2014 Q3	$2K	Buy	2,007 +1,865	+1,313%	+$3.36K	﹤0.01%	3972
2014 Q2	$0	Sell	142 -2,236	-94%	-$5.55K	﹤0.01%	5104
2014 Q1	$7K	Buy	+2,378	New	+$7.83K	﹤0.01%	3033
2013 Q3	–	Sell	-6,338	Closed	-$16K	–	5095
2013 Q2	$16K	Buy	+6,338	New	+$33.2K	﹤0.01%	1945

Other funds holding ECTE

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Tower Research Capital (TRC)'s ECTE Position: Q1 2016 in Review

Tower Research Capital (TRC) sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q1 2016, closing a stake of 2,301 shares — an estimated $3K sold.

Tower Research Capital (TRC) first reported a position in ECTE in Q2 2013 and held it in 8 quarters. The position peaked at $16K in Q2 2013. 15 funds tracked by Wall St. Rank hold ECTE as of Q1 2016.

Tower Research Capital (TRC) reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q1 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 2,301 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q1 2016, an estimated $3K.
Tower Research Capital (TRC) first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q2 2013 and held it in 8 quarters.
Tower Research Capital (TRC)'s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $16K in Q2 2013.
15 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q1 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2016, filed 16 May 2016.